← All Akari Therapeutics PLC filings

Akari Therapeutics PLC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
AKTX
Akari Therapeutics PLC
SCHEDULE: Bank of Montreal Discloses Akari Therapeutics Stake
Bank of Montreal, through its subsidiaries, has reported beneficial ownership of 5.71% of Akari Therapeutics Plc's ordinary shares as of June 30, 2026.
NASDAQ
AKTX
Akari Therapeutics PLC
SCHEDULE: White Lion Capital Discloses 5% Stake in Akari Therapeutics
White Lion Capital LLC has reported beneficial ownership of 5.0% of Akari Therapeutics Plc's ordinary shares, represented by American Depositary Shares, as of August 7, 2026.
NASDAQ
AKTX
Akari Therapeutics PLC
SCHEDULE: MMCAP Discloses 8% Stake in Akari Therapeutics
MMCAP International Inc. SPC and MM Asset Management Inc. have reported an 8% beneficial ownership stake in Akari Therapeutics, Plc.
NASDAQ
AKTX
Akari Therapeutics PLC
SCHEDULE: Akari Therapeutics Insider Discloses 18.4% Stake
Dr. Hoyoung Huh has reported beneficial ownership of 18.4% of Akari Therapeutics Plc's ordinary shares, including options and warrants.
NASDAQ
AKTX
Akari Therapeutics PLC
SCHEDULE 13G: Akari Therapeutics: Dr. Hoyoung Huh Discloses 15.5% Beneficial Ownership Stake
Dr. Hoyoung Huh has reported a significant beneficial ownership of 15.5% in Akari Therapeutics, Plc, comprising over 8.29 billion ordinary shares.